Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Income from Continuing Operations (2017 - 2026)

Lexaria Bioscience's Income from Continuing Operations history spans 10 years, with the latest figure at 1452732.0 for Q1 2026.

  • Quarterly results put Income from Continuing Operations at 1452732.0 for Q1 2026, up 47.19% from a year ago — trailing twelve months through Feb 2026 was 9464154.0 (down 0.89% YoY), and the annual figure for FY2025 was 11877720.0, down 106.97%.
  • Income from Continuing Operations for Q1 2026 was 1452732.0 at Lexaria Bioscience, up from 1575410.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 668006.0 in Q1 2024 to a low of 3750231.0 in Q2 2025.
  • The 5-year median for Income from Continuing Operations is 1695419.0 (2022), against an average of 1870250.65.
  • The sharpest move saw Income from Continuing Operations soared 49.53% in 2024, then tumbled 311.82% in 2025.
  • Year by year, Income from Continuing Operations stood at 1695419.0 in 2022, then soared by 33.24% to 1131823.0 in 2023, then crashed by 137.73% to 2690696.0 in 2024, then skyrocketed by 41.45% to 1575410.0 in 2025, then rose by 7.79% to 1452732.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 1452732.0, 1575410.0, and 2685781.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.